Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07174310 | A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | PHASE3 | RECRUITING | 900 | — | — | Nov 24, 2025 | Jun 30, 2031 | May 6, 2026 | 142 | United States, Australia +15 |
| Arm | Type | Description |
|---|---|---|
| Prasinezumab | EXPERIMENTAL | Participants will receive Prasinezumab as an IV infusion in the double blind treatment period. Upon completion, eligible participants will enter into the Open Label Extension (OLE) phase. |
| Placebo | EXPERIMENTAL | Participants will receive placebo as an IV Infusion. |
| Name | Type | Description |
|---|---|---|
| Prasinezumab | DRUG | Participants will receive Prasinezumab as an IV Infusion as per the schedule mentioned in the protocol. |
| Placebo | DRUG | Participants will receive Placebo as an IV Infusion per the schedule mentioned in the protocol |
Inclusion Criteria: * Body weight within 40-110 kilograms (kg) (88-242 pounds \[lbs\]) and a body mass index within the range 18-34 kg/m2 * Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria * Has received monotherapy treatment * An MDS-UPDRS Part IV score of 0 at screenin...